Stay updated on Pfizer Press Releases

Sign up to get notified when there's something new on the Pfizer Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Pfizer Press Releases page

  1. Check
    5 days ago
    Change Detected
    Summary
    Added a March 9, 2026 press release titled Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis under the Research category. Removed the December 17, 2025 press release ‘PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility’ from the archive.
    Difference
    2%
    Check dated 2026-03-11T23:28:03.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    Added the PADCEV™ + Keytruda® press release dated 02.27.2026 under Medicines and Research and Pipeline; added the corresponding category links. Removed the December 16, 2025 press release 'Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance' from the archive.
    Difference
    1%
    Check dated 2026-03-05T00:51:35.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Two new press releases have been added to the archive: 'Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference' (02.23.2026) and 'U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer' (02.24.2026). Older items were removed: 'TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer' (12.10.2025) and 'Pfizer Declares First-Quarter 2026 Dividend' (12.12.2025).
    Difference
    3%
    Check dated 2026-02-25T20:09:11.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    Added a new press release entry for Pfizer’s BRAFTOVI regimen on 02.17.2026 and introduced the Medicines and Research and Pipeline categories. Removed the Research and Corporate categories and the press release 'Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma' dated 12.09.2025.
    Difference
    1%
    Check dated 2026-02-18T16:47:35.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Added two new press releases: 'Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans' (02.05.2026) and 'FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need' (02.06.2026). Removed two older press releases: 'European Medicines Agency Validates Type II Variation Application for PADCEV™ with KEYTRUDA™ for Certain Patients with Muscle-Invasive Bladder Cancer' (12.01.2025) and 'HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors' (12.06.2025).
    Difference
    3%
    Check dated 2026-02-11T14:11:16.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    New archive entries for February 2026 and December 16, 2025 were added, including 'Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance' and 'Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial'. The archive also removes the December 16 webcast invitation and the 11.21.2025 entry announcing that PADCEV plus Keytruda received FDA approval for certain bladder cancer patients.
    Difference
    8%
    Check dated 2026-02-04T10:25:40.000Z thumbnail image

Stay in the know with updates to Pfizer Press Releases

Enter your email address, and we'll notify you when there's something new on the Pfizer Press Releases page.